Full Press Release Details
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne.
SGMT
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Key Takeaway: Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Price reaction · baseline $5.85 (2024-11-11 close) · hit after-hours · 1 other SGMT headline(s) in the window, move may be shared
day 0 close · peak
+1.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+110%
120-day peak, hindsight
Typical move
5.7%
average across 12 past catalysts
Cash runway
~69 mo
Minimal dilution risk
Lead asset
TVB-2640
Phase 2 · Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease